Giese v. Pierce Chemical Co.

I'll research this case and patent across multiple sources.

Strong foundation. Let me dig into the docket, the reissue, the inventor's affiliation, and any appeal.

Now let me check the appeal history, final disposition, and corporate context for both defendants.

Giese v. Pierce Chemical Co. — Case Overview & Background

The parties. The plaintiff is Roger W. Giese, an individual academic inventor — a professor at Northeastern University in Boston, affiliated with its Barnett Institute of Chemical and Biological Analysis, whose laboratory did pioneering work on avidin–biotin chemistry and on caproylamidobiotin-NHS (see his Northeastern CV, which lists U.S. Patent 4,282,287 and RE31,712 among his inventions and notes that "several companies licensed the invention": CV PDF). This is therefore not an NPE/PAE or university-tech-transfer assertion; it is an inventor suing in his personal capacity, which shapes everything about the case (his own funding constraints and 1981 knowledge of the accused product became central to the laches defense). The defendants are Vector Laboratories, Inc., the California manufacturer of the accused kits, and Pierce Chemical Co. of Rockford, Illinois, a long-established supplier of biochemical reagents and a reseller of Vector's kits — a manufacturer-plus-downstream-distributor pairing that was severed into two companion dockets, Nos. 97-12561-WGY and 97-12562-WGY (D. Mass.), filed November 17, 1997 (per the March 15, 1999 Lawyers Weekly summary: link).

The accused technology and the patents. The accused products are Vector's Vectastain ABC ("avidin–biotin complex") kits — reagent kits used in immunohistochemistry and cell-staining to label and detect cells, including cancer cells, by exploiting the exceptionally tight non-covalent avidin–biotin binding interaction to build successive molecular layers and amplify signal. Giese pleaded only indirect infringement — inducement under § 271(b) and contributory infringement under § 271(c) — expressly not direct infringement, because the kits themselves are unpatented articles and infringement occurs only when end-user researchers practice the claimed methods (29 F. Supp. 2d 33, 36). The asserted patents, all method patents from a single family: U.S. Patent No. 4,282,287 (filed Jan. 24, 1980; issued Aug. 4, 1981), "Biochemical avidin-biotin multiple-layer system" — the parent, claiming the alternating avidin/biotin-ligand ("extender") multilayer build-up on a surface (Google Patents); its reissue RE31,712 (issued Oct. 23, 1984), which is the "'712 patent" actually litigated; and U.S. Patent No. 4,478,914 (issued Oct. 23, 1984), "Process for applying multiple layers of a protein and a ligand extender to a surface," as modified by reexamination certificate B1 4,478,914 (June 17, 1997) — the "'914 patent" (patent PDF). A related patent, 4,684,609 (the "'609 patent"), was the subject of an earlier, separately settled 1995 suit against Vector and became a side issue in claim construction.

Posture, venue, and why it matters. The case was assigned to Judge William G. Young in the District of Massachusetts (identified as Chief Judge in the 1999 ruling), sitting in Boston — a natural forum for Giese (Northeastern) notwithstanding that neither defendant was Massachusetts-based; the two suits were litigated in tandem. The court decided the case almost entirely on summary judgment in two 1998–1999 opinions: the December 1998 ruling, 29 F. Supp. 2d 33 (49 U.S.P.Q.2d 1498), (i) held that the common-law experimental use exception does shield a reagent supplier from inducement/contributory liability when its end users are academic researchers, and that the supplier's profit motive does not forfeit the defense — but denied summary judgment because the defendants failed to prove any actual end user qualified; (ii) granted the defendants laches on a six-year presumption, finding a delay of more than a decade after Giese's 1981 infringement notice barred pre-suit damages; and (iii) denied equitable estoppel for lack of reliance evidence. The March 1999 ruling, 43 F. Supp. 2d 98 (50 U.S.P.Q.2d 1810), then invalidated Claim 25 of the '914 patent and all its dependents (claims 25–27 and 43–73) as impermissibly broadened during reexamination under 35 U.S.C. § 305 and Quantum v. Rodime, except claim 26; granted partial summary judgment that the kits' "preformed complex" was not a monomolecular layer; eliminated lost profits and future royalties as damages theories; applied intervening rights; and held the inequitable-conduct defense waived (CourtListener; Justia).

The case is notable on several counts. It is one of the few decisions giving real content to the experimental use defense for research-tool suppliers — a holding the district court itself framed within Roche Products v. Bolar's "truly narrow" doctrine, later cited in cases such as Akamai v. Limelight, and now regularly discussed (e.g., IPWatchdog, 2025) as the high-water mark before Madey v. Duke (Fed. Cir. 2002) narrowed the doctrine. It is also a leading illustration of how a self-initiated ex parte reexamination can destroy a patent — Giese filed for reexamination of the '914 in May 1995 "in light of additional prior art," and the resulting certificate's broadened claim 25 was held wholly invalid, with no fallback to the original scope. Commercially, the underlying avidin–biotin platform is foundational to immunohistochemistry, ELISA, and blotting, and the Vectastain ABC kit was among the most widely used research reagent systems of the era, so the ruling mattered well beyond the parties. Finally, the laches holding is now largely obsolete: the Supreme Court's 2017 decision in SCA Hygiene Products v. First Quality Baby Products eliminated laches as a damages defense within the six-year § 286 limitations period — meaning Giese's most-cited damages holding no longer states current law, though its experimental-use analysis and its reexamination-broadening analysis remain good citations.

Sourcing caveats. (1) There is no IPR linkage — inter partes review did not exist in 1998; the administrative counterpart here is the 1995–1997 ex parte reexamination, which is the correct proxy. (2) I did not locate a reported Federal Circuit decision on appeal; the litigation appears to have terminated at the district court, but I cannot confirm from these sources whether any appeal was taken or how the residual claims were finally resolved, so treat that as unverified. (3) I was unable to verify Pierce Chemical's ownership chain at the time of suit (its later absorption into the Thermo Fisher "Pierce" brand) within this research session; the observation that Pierce was a reseller of Vector kits, by contrast, is directly supported by the opinions. (4) Patent term dates (the '287/'712 term running from the Aug. 4, 1981 issue date; the '914 from Oct. 23, 1984) are arithmetic under pre-URAA rules, not a finding quoted from any opinion.

I'll research this case systematically across courts, dockets, and PTAB records.

Initial results identify the parties and core docket numbers. Let me dig into the docket, later opinions, and any appellate history.

Now let me pin down the trial outcome, appeal, and any earlier related suit on the '287 patent itself.

Bottom line

The 1997–99 D. Mass. litigation over Roger W. Giese's multilayer-coating patents ended entirely in the defendants' favor, on dispositive motions rather than at trial. In two reported opinions — 29 F. Supp. 2d 33 (Dec. 1998) and 43 F. Supp. 2d 98 (Mar. 1999) — Judge William G. Young (1) barred all pre-suit damages under laches (a >10-year delay), (2) invalidated 33 of the 34 asserted claims of U.S. B1 4,478,914 for impermissible broadening during ex parte reexamination, (3) eliminated lost profits and future royalties, and (4) signaled that Vector was entitled to non-infringement of claim 1 of Re. 31,712 (the reissue of the '287 patent) because the accused "preformed complex" was undisputedly not "monomolecular."

Important framing note on the patent number in the case metadata: U.S. 4,282,287 ('287) was not itself asserted in the 1997 action. It is the parent patent, which was surrendered and reissued as Re. 31,712 ('712); the '287 and '712 cannot both be asserted. The live patents in Giese v. Pierce Chemical were Re. 31,712 and B1 4,478,914, with U.S. 4,684,609 ('609) litigated as a declaratory-judgment/separability side issue. The '287 is relevant here mainly because the court and experts used "the '287 patent" as shorthand for the reissued claims (e.g., Dr. Riordan's report that the accused kit "describes the exact layering process set forth in Dr. Giese's '287 Patent," 43 F. Supp. 2d at 108).

---

Chronological developments

1. USPTO proceedings predating suit (the real "parallel proceedings")

There were no IPRs or PGRs in this case — the patents predate the AIA, and the only PTAB-adjacent activity was a pre-AIA Board of Patent Appeals and Interferences decision in the '609 prosecution.

This reexamination is the single most consequential event in the case: the broadening of claim 25 during reexam became the basis for invalidating it and 32 dependents, and the reexam also failed as a laches excuse (see below).

2. Earlier, related litigation

Giese had sued Vector in July 1995 on the '609 patent — but deliberately did not assert the '914 or '712 in that suit. The 1998 laches opinion treats this as evidence cutting against Giese, because it showed he was capable of suing while sitting on the '712/'914. (29 F. Supp. 2d at 40–42.)

3. Filing and initial pleadings

• 1997-11-17 — Giese files suit in the U.S. District Court for the District of Massachusetts. Two docket numbers appear in the record: Nos. 97-12561-WGY and 97-12562-WGY (Giese v. Pierce Chemical Co. and Giese v. Vector Laboratories, Inc.), consolidated before Judge Young. Plaintiff's counsel: Ian Crawford (Boston). Defense: Peter G. Carroll, Duane C. Blake (Cambridge) and Thomas Currier.
• Amended Complaint asserted only indirect infringement — contributory infringement and inducement — of the '712 and '914, targeting Vector's manufacture and Pierce's resale of the Vectastain ABC Kit. Critically, "Giese includes no count for direct infringement," because the kits themselves are unpatented reagents and infringement of the method claims required use by end-user researchers. (29 F. Supp. 2d at 35–36.)
• Answer/counterclaims: Vector and Pierce asserted declaratory judgment counterclaims of invalidity and unenforceability of the '712 and '914. The court sustained jurisdiction over those counterclaims because "Giese has actually filed suit and Vector has actually produced an accused device." (43 F. Supp. 2d 98.)

4. December 1998 opinion — three summary judgment motions (29 F. Supp. 2d 33)

Reported at 29 F. Supp. 2d 33 (D. Mass. 1998), 1998 WL 856576; summarized at Mass. Lawyers Weekly No. 02-260-98 (published 1998-12-21).

1. Experimental use / non-infringement — DENIED (but doctrine accepted). Judge Young held the common-law experimental use exception is viable and, "to the extent its elements are otherwise satisfied, shields Vector and Pierce from claims of contributory infringement or inducement." He rejected Giese's argument that the defendants' profit from kit sales forfeits the defense: "It makes no difference that Vector and Pierce benefit financially by selling the kits because they are selling kits to end-users who have the right to practice the patented methods." But SJ was denied because the defendants made no showing that any actual end user qualified for the exemption. This holding is the case's most-cited legacy — it was picked up in Akamai Techs. v. Limelight Networks (Fed. Cir. en banc) and is discussed in IPWatchdog's 2025-05-20 treatment of the experimental use exemption.
2. Laches — GRANTED. Applying the six-year presumption from Aukerman, the court found over a decade of unexplained delay (Giese knew of the kits in 1981, first charged infringement that year, and repeatedly made rejected licensing overtures), held the 1995–97 reexamination "has no bearing on the preceding decade of delay," and rejected poverty and contractual restriction as excuses. Result: Giese barred from recovering damages for any infringement occurring before filing.
3. Equitable estoppel — DENIED. Although estoppel could bar all relief including injunctive relief, the defendants relied almost entirely on the laches presumption and failed to prove the distinct reliance element with competent evidence (seven years of silence, broken by a December 1991 letter, was insufficient on this record).

5. March 1999 opinion — six more partial summary judgment motions (43 F. Supp. 2d 98)

Reported at 43 F. Supp. 2d 98 (D. Mass. 1999), 1999 WL 166809; Mass. Lawyers Weekly No. 02-033-99 (1999-03-15). The court granted in part and denied in part Vector's six motions. Key rulings:

• Invalidity for impermissible broadening in reexamination — GRANTED as to claim 25 and claims 26–27 and 43–73 (all but claim 26). Applying 35 U.S.C. § 305 and Quantum Corp. v. Rodime, the court construed reexamined claim 25 and found the deletion of the washing step enlarged scope. The court was explicit that the remedy is total: invalidity, not restoration of the original claim scope. Claim 26 survived only because Vector made no independent showing against it.
• "Monomolecular" — GRANTED for Vector. Construing the claim term, the court found it undisputed that the Vectastain kit's "preformed complex" is **

Bottom line

Only one attorney can be documented as counsel of record for the plaintiff, Roger W. Giese, in Giese v. Pierce Chemical Co., No. 97‑12561‑WGY (D. Mass.) (with companion case No. 97‑12562‑WGY): Ian Crawford, a Boston litigator, identified in the contemporaneous docket reports as "Ian Crawford for the plaintiff." No co‑counsel, local counsel, or in‑house counsel for Giese is documented in any source I could locate.

Plaintiff's counsel

Source basis (and its limits)

• Massachusetts Lawyers Weekly summaries of Judge William G. Young's opinions give the appearance line directly:
  • Giese v. Pierce Chemical Co., Lawyers Weekly No. 02‑260‑98 (29 pages) (Young, J.) (USDC) (Civil Action No. 97‑12561‑WGY) — "Ian Crawford for the plaintiff" (defense: Peter G. Carroll, Duane C. Blake, Thomas Currier). https://masslawyersweekly.com/1998/12/21/patent-and-trademark-contributory-infringement-experimental-use/
  • Giese v. Pierce Chemical Co., Lawyers Weekly No. 02‑033‑99 (33 pages) (Young, C.J.) (Docket Nos. 97‑12561‑WGY and 97‑12562‑WGY) — "Ian Crawford for the plaintiff; Peter G. Carroll, Duane C. Blake and Thomas Currier for the defendants." https://masslawyersweekly.com/1999/03/15/patent-and-trademark-broadening-of-claims-method-of-chemical-layer-attachment/
• Feature article, "Marketing Of Patented Kit To Nonprofits Is Allowed" (Mass. Lawyers Weekly, Dec. 21, 1998), quotes "Plaintiff's counsel Ian Crawford of Boston." https://masslawyersweekly.com/1998/12/21/marketing-of-patented-kit-to-nonprofits-is-allowed/
• Firm/office confirmation: Massachusetts appellate courts attorney detail listing Ian Crawford, Todd & Weld, 28 State Street, Boston (https://www.ma-appellatecourts.org/attorney/[544475](/patent/544475)); professional biography entries (https://prabook.com/web/ian.crawford/[1204825](/patent/1204825)).

Caveats — what is not verified

• No PACER docket sheet was pulled. D. Mass. CM/ECF for 1997 is not freely available, and no CourtListener/Recap docket with an attorney list surfaced. The identification above rests on the Lawyers Weekly docket/opinion summaries (which are derived from the docket and opinions themselves) rather than the docket image. A PACER pull of No. 1:97‑cv‑12561‑WGY would be the confirming step and would also show any pro hac vice appearances or withdrawals.
• Crawford's firm at the time of filing is uncertain. The 1998/1999 sources say only "of Boston"; his Todd & Weld affiliation is documented by later directory listings, so it should be treated as probable rather than confirmed for 1997–99. He should not be described as Todd & Weld counsel "of record" in 1997 without a docket check.
• No other plaintiff-side appearances are documented. I found no evidence of co‑counsel, local counsel, or in‑house representation for Giese, and no indication that he proceeded pro se. Nothing in the opinions suggests sealed filings affecting the attorney list.
• No parallel PTAB/IPR proceedings exist for these patents (they predate the AIA; the relevant PTO proceedings were the 1982–84 reissue and the 1995–97 reexamination of the '914 patent, which Giese handled himself before the Examiner).

Case-fit note (for the larger project)

Counsel research should flag that U.S. Patent No. 4,282,287 is the original Giese patent, but the two merits opinions are grounded on Re. 31,712 and B1 4,478,914 (the '287 patent's reissue/reexamined progeny); the '287 patent itself appears in the laches chronology (Giese knew of Vector's product by August 1981) rather than as a claim vehicle. Any counsel‑experience coding should therefore tie Ian Crawford's role to the reissue/reexamination family, not to the '287 patent alone.

I'll research the counsel of record for Pierce Chemical Co. in this case, starting with the docket and patent details.

Found the core case. Now let me pin down the specific counsel-firm affiliations and docket details.

Counsel of Record for the Defendant(s) — Giese v. Pierce Chemical Co.

Threshold correction to the case metadata

Before naming counsel, one important caveat: the case as actually litigated had two defendants, not one — Vector Laboratories, Inc. (manufacturer of the accused "Vectastain ABC Kit") and Pierce Chemical Co. (a reseller of the kits). The two were litigated under two consolidated D. Mass. docket numbers, 97‑12561‑WGY and 97‑12562‑WGY, before Chief Judge William G. Young.¹ Also, although the metadata lists only U.S. Patent No. 4,282,287, the operative pleadings and rulings also addressed Re. 31,712, B1 4,478,914, and 4,684,609.² This matters for the counsel question because the press reports of the rulings identify a single, joint defense team appearing for both defendants rather than separate Pierce-only counsel.

The defense team

Sourcing and its limits — read this before relying on the table

• What is well sourced: the roster of three defense attorneys and the two docket numbers come directly from the Massachusetts Lawyers Weekly digest of the March 15, 1999 decision: "Ian Crawford for the plaintiff; Peter G. Carroll, Duane C. Blake and Thomas Currier for the defendants (Docket Nos. 97-12561-WGY and 97-12562-WGY)." The December 21, 1998 article adds the Cambridge identification for Blake and Carroll and names Blake as counsel for "the defendant biotech company."¹ ⁴ ⁵
• What is NOT well sourced: I could not verify (a) a Pierce-specific as opposed to Vector-specific engagement, (b) Blake's and Currier's firms, or (c) formal "lead counsel" designations from the docket itself. The rulings and press coverage treat the defense as a joint representation; if Pierce had separate counsel, the published opinions and Lawyers Weekly digests do not surface it.
• No PACER/RECAP docket sheet was retrieved. I was unable to pull the docket entries (appearances, pro hac vice motions, withdrawals) for either 97‑12561‑WGY or 97‑12562‑WGY. Nothing here is drawn from a docket entry, so all role characterizations above are inferences from opinions and press coverage, not from ECF records.
• No sealing issue identified — this was a 1997–1999 District of Massachusetts case; the opinions at 29 F. Supp. 2d 33 and 43 F. Supp. 2d 98 are public and unpublished sealing problems were not noted in the sources reviewed. That said, I did not review the full docket, so I cannot affirmatively rule out sealed filings.
• No PTAB/IPR parallel proceeding exists. The patents expired long before the AIA's IPR regime; the only post-grant proceeding in the record is Giese's own 1995–1997 ex parte reexamination of the '914 patent, which figures heavily in the 1999 invalidity ruling and the laches analysis.²

Why this defense team's work is worth flagging in your research

The joint defense won on laches (summary judgment granted, barring pre-suit damages on a 13+ year delay) and, in the March 1999 ruling, largely on impermissible enlargement during reexamination of the '914 claims. The experimental-use holding in the 1998 opinion (29 F. Supp. 2d at 36) remains the most-cited proposition from the case and is still invoked in the wake of Akamai on indirect infringement.⁶ Blake and Carroll both gave on-record interviews framing the decisions as precedent-setting in Massachusetts — useful color if you are profiling the defense strategy.

Recommended next step to close the gaps

To convert the above from "press-reported" to "docket-verified," pull the appearance entries in D. Mass. 1:97‑cv‑12561‑WGY and 1:97‑cv‑12562‑WGY (the second number is likely the companion/consolidated action) and confirm: (i) whether Pierce filed a separate answer with separate counsel; (ii) the firms of record for Blake and Currier; and (iii) any pro hac vice admissions. I would not state Blake's or Currier's firms in any filed work product until that check is done.

---

Sources

1. Giese v. Pierce Chem. Co., 43 F. Supp. 2d 98 (D. Mass. 1999), via CourtListener, https://www.courtlistener.com/opinion/[2423014](/patent/2423014)/giese-v-pierce-chemical-co/
2. Massachusetts Lawyers Weekly, "Patent And Trademark – Broadening Of Claims – Method Of Chemical Layer Attachment," Mar. 15, 1999, https://masslawyersweekly.com/1999/03/15/patent-and-trademark-broadening-of-claims-method-of-chemical-layer-attachment/
3. Martindale-Hubbell / Lawyers.com profiles of Peter Gregory Carroll (Medlen & Carroll, LLP), https://www.martindale.com/attorney/peter-gregory-carroll-[672245](/patent/672245)/ ; https://www.lawyers.com/san-francisco/california/peter-gregory-carroll-672245-a/
4. Massachusetts Lawyers Weekly, "Marketing Of Patented Kit To Nonprofits Is Allowed," Dec. 21, 1998, https://masslawyersweekly.com/1998/12/21/marketing-of-patented-kit-to-nonprofits-is-allowed/
5. Massachusetts Lawyers Weekly, "Patent And Trademark – Contributory Infringement – 'Experimental Use'," Dec. 21, 1998, https://masslawyersweekly.com/1998/12/21/patent-and-trademark-contributory-infringement-experimental-use/
6. Giese v. Pierce Chem. Co., 29 F. Supp. 2d 33 (D. Mass. 1998), https://law.justia.com/cases/federal/district-courts/FSupp2/29/33/[2472263](/patent/2472263)/ ; citing reference collected at http://g.casetext.com/case/giese-v-pierce-chemical-co-2/how-cited